INTRODUCTION
Cirrhosis is a late stage progressive hepatic fibrosis characterized by distortion of hepatic architecture and the formation of regenerative nodules. Although con sidered potentially reversible in some clinical scenarios, in its advanced stages, liver cirrhosis is associated with high mortality and the only treatment option may be liver transplantation [1] . Patients with cirrhosis are susceptible to a variety of complications such as variceal bleeding, ascites, spontaneous bacterial peritonitis (SBP), hepatic encephalopathy, hepatocellular carcinoma, hepatorenal syndrome, hepatopulmonary syndrome and portal vein thrombosis [1] . The prognosis of cirrhosis is highly variable because it is influenced by a number of factors including etiology, severity, presence of complications, and comorbidities. Mortality rate increases significantly once decompensation occurs [2] . Changes in the growth hormoneinsulinlike growth factor (GHIGF) axis occur as a result of liver disease and has been reported in cirrhosis [3, 4] . GH and IGF Ⅰ have important anabolic effects on the metabolism of proteins, carbohydrates and lipids [5] . GH is a pep tide hormone released from anterior pituitary that stimulates growth, cell reproduction and regenerations while exerting metabolic effects on bone, cartilage, fat, muscles, heart and the immune system [68] .
In the liver, GH activation of GH receptors induces IGF-Ⅰ gene transcription, and the subsequent synthesis and release of IGFⅠ to plasma [9] . However, the actions of IGFⅠ are tightly controlled by the binding of IGF to binding proteins (IGFBP1 to 6). The IGFBPs carry IGFs in the serum and regulate their activity and bioavailability [10] . IGFBP3 is the major binding protein of IGF and carries 80%90% of circulating IGFⅠ. The IGFBP3 is predominantly produced in the liver and synthesized in Kupffer cells. It forms a 150 kDa ternary complex with IGFs and the acidlabile subunit [7, 9] . Low serum concentrations in both IGFⅠ and IGFBP 3 have been reported in patients with cirrhosis vs healthy controls. This likely reflects decreased hepatic synthesis function [5, 1113] . In fact, some studies reported that IGFBP3 serum levels are abnormally low in patients with liver cirrhosis and correlated with several variables associated with the intensity of liver dysfunction [5, 7] . Even though these reports suggest the clinical utility of monitoring circulating IGFBP3 in cirrhosis, there is little data on the prognostic significance of this biomarker. The aim of this study was to investigate the relationship between serum IGFBP3 levels and prognosis in both outpatients with stable cirrhosis and in patients hos pitalized for acute decompensation (AD).
MATERIALS AND METHODS

Patients
This prospective study included two cohorts of adult patients (≥ 18 years of age) with liver cirrhosis in the University Hospital of the Federal University of Santa Catarina. The diagnosis of cirrhosis was established either histologically (when available) or by combination of clinical, imaging and laboratory findings in patients with evidence of portal hypertension. The first cohort was comprised of patients with stable cirrhosis in the outpatient clinic. In this case, patients in the following situations were excluded: Diagnosis of hepatocellular carcinoma; interferonbased therapy over the last 30 d; or refusal or inability of the patient to understand the terms of the informed consent.
The second cohort included patients admitted to the emergency room due to AD of liver cirrhosis. In this group, the following exclusion criteria were adopted: Hospitalization for elective procedures; admissions not related to complications of liver cirrhosis; and hepa tocellular carcinoma outside Milan criteria. Exclusion criteria for both groups also included: Pregnancy; chronic renal failure requiring hemodialysis; severe heart disease; severe chronic pulmonary disease; and active extrahepatic cancer. The study protocol complies with ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee on Human Research of the Federal University of Santa Catarina.
Methods
This initial cohort was initially evaluated from June to October 2012. The development of complications, mortality, or liver transplantation was assessed by periodic phone calls and during outpatient visits. Patients also underwent clinical and laboratory evaluation yearly (2013 and 2014) in predefined study visits. The second cohort included subjects hospitalized for AD between January 2011 and November 2013. AD was defined by acute development of hepatic encephalopathy, large ascites, gastrointestinal bleeding, bacterial infection or any combination of these. Patients were evaluated within 24 h of admission by one of the researchers involved in the study. They were followed during their hospital stay and 30 and 90d mortality was evaluated by phone call in case of hospital discharge. In case of more than one hospital admission during the study periodonly the most recent hospitalization was considered.
The following clinical variables were collected for all patients: Age, gender, etiology of cirrhosis, history of previous decompensation, current complications of cirrhosis, active alcoholism and regular propranolol and omeprazole use. All subjects underwent laboratory evaluation including total leukocytes, serum sodium, creatinine, international normalized ratio (INR), albumin, Creactive protein (CRP), total bilirubin and IGFBP3. In patients hospitalized for AD of cirrhosis, blood samples were obtained on the first and third day after admission.
Active alcoholism was defined as an average overall consumption of 21 or more drinks per week for men and 14 or more drinks per week for women during the 4 wk before enrollment (one standard drink is equal to 12 g absolute alcohol) [14] . Hospitalized individuals with a suspected infection at admission received a clinical examination to confirm this diagnosis and to establish the primary source of infection. Diagnosis of infection was made according to the criteria of Center for Disease Control [15] . A diagnostic paracentesis was performed in all patients with ascites at admission. SBP was diagnosed when the neutrophil count in the ascitic fluid was ≥ 250 neutrophils/mm 3 in the absence of an intraabdominal source of infection regardless of negative culture [16] . All patients with SBP received ceftriaxone plus weightbased intravenous albumin in the first and third day after diagnosis. Hepatic encephalopathy was graded according to WestHaven criteria [17] . If this was present, a precipitant event was actively investigated and lactulose was initiated, and the dose was adjusted as needed. All subjects with acute variceal bleeding received intravenous octreotide, an antibiotic (either oral quinolone or intravenous ceftri axone), and underwent urgent therapeutic endoscopy after stabilization.
The severity of liver disease was estimated using the ChildPugh classification system [18] and model for endstage liver disease (MELD) [19] calculated based on laboratory tests performed at admission in the case of hospitalized patients. Acuteonchronic liver failure (ACLF) was defined as proposed by the EASLCLIF Consortium [20] .
IGFBP-3 serum levels
In patients with stable cirrhosis, IGFBP3 levels were measured at baseline (2012) and at second re evaluation (2014). In hospitalized subjects, IGFBP3 levels were measured in serum samples collected in the first and in the third day after admission and stored at 80 ℃ until use. The IGFBP3 levels were measured by immunochemiluminescence (Immulite ® 2000, Diagno stic Products Corp., Los Angeles, CA, United States). The reported analytical sensitivity of this assay is 0.50 mcg/mL. 
Statistical analysis
IGFBP-3 in outpatients with stable cirrhosis
In patients with stable cirrhosis, IGFBP3 levels were positively correlated with total leukocytes (r = 0.215, P = 0.011) and albumin levels (r = 0.579, P < 0.001).
A negative correlation was observed between IGFBP3 levels and INR (r = 0.412, P < 0.001), total bilirubin (r = 0.329, P < 0.001), CRP (r = 0.265, P = 0.002) and MELD (r = 0.327, P < 0.001). No significant correlations were observed between IGFBP3 and other studied variables.
Significantly lower IGFBP3 median levels were observed in ChildPugh B/C patients (1.38 mcg/mL vs 1.88 mcg/mL, P < 0.001), in those with previous decom pensation of cirrhosis (1.58 mcg/mL vs 2.19 mcg/mL, P = 0.012), hospitalization secondary to complications of cirrhosis (1.57 mcg/mL vs 1.95 mcg/mL, P = 0.052), and those with a history of ascites (1.53 mcg/mL vs 1.85 mcg/mL, P = 0.024). Previous variceal bleeding or hepatic encephalopathy as well as an etiology of cirrhosis had no impact on IGFBP3 levels (P > 0.05).
The median followup of patients with stable cirrhosis was 20 mo. During the study period, 17 patients died and 11 received liver transplantation. Bivariate analysis showed that progression to death or liver transplantation was associated with previous ascites (70.4% vs 42.3%, P = 0.009), history of hospitalization for complications of cirrhosis (88.9% vs 65.8%, P = 0.018), and ChildPugh B/C (70.4% vs 24.3%, P < 0.001) ( Table 2 ). In addition, those with unfavorable outcome showed a higher median total bilirubin (1.80 mg/dL vs 0.90 mg/dL, P < 0.001), INR (1.27 vs 1.16, P < 0.001), CRP (4.51 mg/L vs 3.50 mg/L, P = 0.014), MELD score (11.98 ± 2.24 vs 9.32 ± 1.97, P < 0.001) and lower sodium (136.00 mEq/L vs 138.00 mEq/L, P = 0.022), albumin (3.11 ± 0.39 g/dL vs 3.52 ± 0.44 g/dL, P < 0.001) and IGFBP3 values (1.44 mcg/mL vs 1.74 mcg/mL, P = 0.027). A stepwise forward logistic regression analysis was performed including the following variables with P < 0.05 in bivariate analysis: Previous ascites, history of hospitalization for complications of cirrhosis, albumin, INR, total bilirubin, CRP, sodium, and IGFBP3. Multivariate analysis showed that only albumin (OR = 0.183, 95%CI: 0.0530.631, P = 0.007) and total bilirubin (OR = 2.482, 95%CI: significant.
RESULTS
Characteristics of included patients
The study included 138 patients with stable cirrhosis and 189 subjects hospitalized for AD of cirrhosis. Table  1 lists the characteristics of the included patients. In the cohort of stable cirrhosis, the mean age was 53.6 ± 12.5 years, 92.8% were Caucasians with a predominance of men (70.3%). A previous history of cirrhosis decompensation was observed in 75.4% of the sample and only 3.6% of subjects reported active alcoholism during the past month. Regular propranolol and PPI use was 63.0% and 50.0% of the patients, respectively. The mean MELD score was 9.84 ± 2.28 and 66.7% of subjects were ChildPugh A.
In the group hospitalized for AD, the mean age was 53.6 ± 11.6 years, 68.6% were Caucasians and 73.0% were males. Previous decompensation was (Figure 1 ). Twentyseven patients developed variceal bleeding during followup. Those patients exhibited similar base line IGFBP3 levels when compared to those who did not develop this complication (1.74 mcg/mL vs 1.69 mcg/mL, P = 0.478).
Onehundred and nine patients underwent labo ratory evaluation in 2014, and 12 subjects refused blood collection. Of those who did not receive liver transplantation, IGFBP-3 significantly decreased at the second assessment (1.67 mcg/mL vs 1.74 mcg/mL, P = 0.013). However, in patients who underwent liver transplantation, a significant increase in IGFBP3 was observed (3.81 mcg/mL vs 1.33 mcg/mL, P = 0.008). Actually, IGFBP3 increased in all nine patients, and its levels were restored to normal after transplantation in five subjects.
Prognostic significance of IGFBP-3 in patients hospitalized for AD of cirrhosis
In hospitalized patients, IGFBP3 levels were positively correlated with sodium (r = 0.173, P = 0.018) and albumin levels (r = 0.422, P < 0.001). A negative correlation was observed between IGFBP3 levels and INR (r = 0.437, P < 0.001), total bilirubin (r = 0.278, P < 0.001), CRP (r = 0.365, P < 0.001), MELD (r = 0.373, P < 0.001), and CLIFSOFA (r = 0.410, P < 0.001). Significantly lower levels of IGFBP3 were observed in ChildPugh C patients (0.73 mcg/mL vs 1.13 mcg/mL, P < 0.001), in those with ascites (0.76 mcg/mL vs 1.22 mcg/mL, P < 0.001), hepatic encepha lopathy (0.85 mcg/mL vs 1.12 mcg/mL, P = 0.001), ACLF (0.78 mcg/mL vs 1.02 mcg/mL, P = 0.007) and bacterial infection at admission (0.66 mcg/mL vs 1.11 mcg/mL, P < 0.001). The etiology of cirrhosis had no impact on IGFBP3 levels (P > 0.05).
Overall 30d mortality was 24.3%, and it was associated with active alcoholism in bivariate analysis (Table 3 ) (50.0% vs 31.5%, P = 0.023) as well as ascites (76.1% vs 39.9%, P < 0.001), hepatic ence phalopathy (84.8% vs 51.0%, P < 0.001), bacterial infection (48.9% vs 19.6%, P < 0.001), ChildPugh C (73.9% vs 28.7%, P < 0.001), ACLF at admission (63.0% vs 11.2%, P < 0.001), lower median SpO2/FiO2 ratio (442.86 vs 461.90, P < 0.001), and higher MELD score (22.44 ± 6.95 vs 14.35 ± 5.00, P < 0.001). The 30d mortality was also related to higher median leucocyte count (8.46 × 10 9 /L vs 6.59 × 10 9 /L, P = 0.005), creatinine (1.80 mg/dL vs 1.00 mg/dL, P < 0.001), INR (1.60 vs 1.38, P < 0.001), CRP (24.80 mg/L vs 8.40 mg/L, P = 0.002), total bilirubin (3.10 mg/dL vs 1.51 mg/dL, P < 0.001) as well as lower mean albumin (1.98 ± 0.51 g/dL vs 2.47 ± 0.70 g/dL, P < 0.001), lower median sodium (134.00 mEq/L vs 136.00 mEq/L, P = 0.011), and IGFBP3 levels (0.63 mcg/mL vs 1.05 mcg/mL, P < 0.001).
A stepwise forward logistic regression analysis was performed including the following variables with P < 0.010 in the bivariate analysis: Ascites, hepatic encephalopathy, infection at admission, SpO2/FiO2 ratio, leukocyte count, creatinine, INR, albumin, CRP, total bilirubin, and IGFBP3. In this regression analysis, the 30day mortality was independently associated with creatinine (OR = 5.331, 95%CI: 2.56311.090, P < 0.001), INR (OR = 5.830, 95%CI: 1.49222.785, P = 0.011), SpO2/FiO2 ratio (OR = 0.985, 95%CI: 0.9750.995, P = 0.004), and IGFBP3 (OR = 0.332, 95%CI: 0.1200.915, P = 0.033).
Fiftyfour patients died and three subjects under went liver transplantation during 90 d of followup. The KaplanMeier survival probability at 90d was 80.4% in patients with IGFBP3 ≥ 0.86 mcg/mL and 56.1% for subjects with IGFBP3 < 0.86 mcg/mL (P < 0.001) (Figure 2A ). For the prediction of 90d mortality, the IGFBP3 at a cutoff of 0.86 mcg/mL showed a sensitivity of 63% and a specificity of 65%. The negative predictive value was 80% with a positive predictive value of only 44%. Figure 2A exhibited KaplanMeier curves for mortality during the followup period according to the presence of ACLF and IGFBP3 categories. The Kaplan Meier survival probability at 90d was 89.5% in patients without ACLF and IGFBP3 ≥ 0.86 mcg/mL. It was 70.7% for those with IGFBP3 < 0.86 mcg/mL only, 42.9% for those with ACLF only, and 20.8% for patients with both ACLF and IGFBP3 < 0.86 mcg/mL (P < 0.001, longrank test). Similarly, the 90d survival was 90.8% in patients with ChildPugh A/B and with IGFBP3 ≥ 0.86 mcg/mL, 78.9% for those with IGFBP3 < 0.86 mcg/mL only, 54.8% for those with ChildPugh C only, and 36.4% for ChildPugh C patients with IGFBP3 < 0.86 mcg/mL (P < 0.001) ( Figure 2B ).
The MELD score was dichotomized as ≥ 17 and < 17 based on ROC curve. The 90d KaplanMeier survival probability was 90.7% in patients with MELD < 17 and IGFBP3 ≥ 0.86 mcg/mL, 80.5% for those with MELD < 17 and IGFBP3 < 0.86 mcg/mL, 56.3% for those with MELD ≥ 17 and IGFBP3 ≥ 0.86 mcg/mL, and 31.7% for patients with both MELD ≥ 17 and IGFBP3 < 0.86 mcg/mL (P < 0.001) ( Figure 2C) .
The IGFBP3 levels were available for 163 patients at the third day of hospitalization and showed a significant decline vs admission values (0.76 mcg/mL vs 0.94 mcg/mL, P < 0.001). However, neither the magnitude Insulin-like growth factor-binding protein 3; MELD: Model for end-stage liver disease; MAP: Mean arterial pressure; SpO2/FiO2: Oxygen saturation to fraction of inspired oxygen ratio; ACLF: Acute-on-chronic liver failure.
nor the occurrence of IGFBP3 decline was related to the severity of cirrhosis or bad prognosis (data not shown). In addition, IGFBP3 measured at the third day showed similar performance to admission levels when used at its best cutoff for prediction of 90d mortality (0.68 mcg/mL). These metrics offered a sensitivity of 64%, specificity of 65%, negative predictive value of 83% and positive predictive value of 41%.
IGFBP-3 levels after hospital discharge
The 30 patients evaluated during hospitalization under went laboratory analysis within a median 105 days after discharge. These were compared at two time points to investigate the impact of AD on IGFBP3 levels. Vs inpatient assessment, significantly higher median IGFBP3 levels were observed with outpatient evaluation (1.51 mcg/mL vs 1.07 mcg/mL, P < 0.001). Likewise, an increase in IGFBP3 levels at outpatient evaluation were observed in 24 out of 30 patients included in this analysis (80%).
DISCUSSION
Even though the course of cirrhosis varies according to several factors, the need for prognostic markers and scoring systems is critical to manage individuals facing different therapeutic options [21] . It was previously shown that IGFBP3 levels in cirrhosis are related to the severity of liver dysfunction. This marker undergoes only slight influence from other factors not related to liver synthesis capacity. Therefore, IGFBP3 is a potential and underexplored prognostic biomarker in liver cirrhosis.
Here, the IGFBP3 levels correlated with several variables directly or indirectly associated with the in tensity of liver dysfunction in both stable and decom pensated patients. These findings agree with previous studies, which demonstrated an association between lower IGFBP3 levels and the severity of liver dis ease [5, 7, 10, 2124] . In a recent study including patients with AD of cirrhosis, we showed that patients with more severe liver dysfunction exhibited lower IGFBP3 levels -these levels were not influenced by other parameters such as gender, etiology of cirrhosis and comorbidities [25] .
In addition, this study showed that IGFBP3 increased significantly after liver transplantation as well as after hospital discharge. These findings reinforce the impact of hepatic synthetic function on IGFBP3 levels and support its utility as a potential biomarker for assessment of liver function.
In patients with stable cirrhosis, death or liver transplantation during followup was associated with lower IGFBP3 levels in bivariate analysis. In addition, transplantfree survival was significantly shorter in subjects with IGFBP3 < 1.67 mcg/mL. Data about the prognostic significance of IGFBP3 in cirrhosis are scarce. IGFBP3 was evaluated in 354 patients with alcoholinduced liver disease from a large multicenter trial of the effect of malotilate on survival [26] . The mean followup period was 569 d and low IGFBP3 levels were associated with poor prognosis, especially at a cutoff of 1.35 mcg/mL [26] . The difference between this cutoff and that in the present study probably reflects methodological issues or disparities in the severity of the disease across the cohorts. It is important to note that the European study included both patients with and without cirrhosisno detailed analysis of only those with cirrhosis was provided [26] . In our data, IGFBP3 was not associated with death or liver transplantation in the logistic regression analysis in stable cirrhosis. This can be explained by the relatively low number of events in this cohort. Nevertheless, these results indicate the potential of IGFBP3 as a prognostic marker in stable cirrhosis.
In patients hospitalized for AD of cirrhosis, lower IGFBP3 levels were associated with shortterm mortality in both bivariate and multivariate analysis. There is no data about IGFBP3 prognostic value in this setting. It is possible that suppressed IGFBP3 reflects the acute deterioration of hepatic function as suggested by its lower levels in hospitalized cirrhosis vs outpatients. The KaplanMeier survival probability at 90 d was significantly worse in patients with IGFBP3 < 0.86 mcg/mL vs control subjects (56.1% vs 80.4%, P < 0.001). This cutoff is markedly lower than the limits suggested by Møller et al [26] as well as in our study for stable cirrhosis. This likely reflects the severe deterioration of hepatic function in AD of cirrhosis. The significance of IGFBP3 in AD of cirrhosis was evaluated according to two of the most important prognostic parameters in this setting: The presence of ACLF and Child-Pugh Classification. The ACLF definition used here was based on a modified version of the SOFA score (CLIF-SOFA) and was first proposed by the EASCLIF Consortium in a large multicenter trial and subsequently validated [20, 27] . Patients who presented with higher IGFBP3 and without ACLF showed good prognosis (90d survival approximately 90%). However, even in the absence of ACLF, low IGFBP3 was asso ciated with worse prognosis and a 90d survival of 70.7%. Similarly, in the presence of ACLF, higher IGFBP 3 was associated with 90d survival of 42.9% vs 20.8% for those with both ACLF and low IGFBP3. These results indicate that combining IGFBP3 and ACLF definition provided a well-defined four-level stratification for shortterm prognosis in patients with cirrhosis hospitalized for AD. Similar results were observed for ChildPugh Classification and MELD score although with a less clear stratification than that observed by using ACLF.
This study does have some limitations. The relatively small number of events in the stable cohort may have influenced the results -especially concerning regression analysis. In fact, regarding stable patients with cirrhosis there is still a need for validation of our results in larger cohorts with a longer followup before this biomarker is incorporated into clinical practice. Another limitation that we should highlight is the fact that we included a very heterogeneous population in distinct clinical scenarios and no specific treatment guidelines were created for the purpose of this study. Therefore, variations in the approach to specific cases are expected. In addition, the underlying liver disease status (if active or not) was not investigated. However, this issue is common in almost all studies investigating biomarkers in clinical settings. In addition, patients were evaluated accord ing to standardized charts developed specifically for the purpose of the study and were followed both in outpatient clinic and in the ward by the same medical team. This minimized the impact of nonstandardized approach.
In conclusion, in patients with cirrhosis IGFBP3 levels correlated with several variables associated with severity of liver disease and improved significantly after discharge and after liver transplantation, indicating the impact of impaired hepatic function on its levels. Lower IGFBP3 levels were associated with worse long term prognosis in outpatients with stable cirrhosis and worse shortterm prognosis in those hospitalized for AD. These findings suggest that measurement of circulating IGFBP3 is of prognostic relevance and can be incorporated into clinical practice to improve the care of patients with liver cirrhosis.
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